Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von M Luiza Caramori und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Renal Insufficiency, Chronic, Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Diagnostics.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population. We investigated a large US database to determine whether CKM therapies were used, beneficial and safe among patients with Type 1 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with Type 1 diabetes in Optum's de‐identified Market Clarity database, consisting of claims and electronic medical records data, between January 1, 2016, and December 31, 2023, were included. Patients who had their first CKM therapy prescription during the study period were propensity score‐matched to those not on CKM therapy. The 253 patients with sufficient data to assess changes in urinary albumin‐to‐creatinine ratio (UACR) were included in the analyses. Rates of hypoglycaemia and diabetic ketoacidosis were also assessed.
Results
CKM therapy was used by more than 10% of the patients with Type 1 diabetes and CKD. At baseline, average age was 52 years, HbA1c 8.1%, eGFR 77 mL/min/1.73 m 2 . UACR median was 60.8 mg/g. Time to 30% or more UACR reduction was shorter among patients on CKM therapy versus controls [HR 0.76 (CI 0.61–0.95), p = 0.0158]. Rates of hypoglycaemia and diabetic ketoacidosis were not increased among patients on CKM therapy.
Conclusions
CKM therapy was frequently used in patients with Type 1 diabetes and CKD, associated with UACR reduction and safe. These clinically relevant data warrant confirmation in randomised clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Roche Diagnostics Corp, Indianapolis, Indiana, USA.
- University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Ambarish Pandey, Peter Rossing
Förderung
- Roche Diagnostics
Zitieren
APA
Caramori, M. L., Repetto, E., Perkins, C., Pandey, A., & Rossing, P. (2026). Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70640
Vancouver
Caramori ML, Repetto E, Perkins C, Pandey A, Rossing P. Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70640
BibTeX
@article{Caramori2026,
author = {Caramori, M Luiza and Repetto, Enrico and Perkins, Christopher and Pandey, Ambarish and Rossing, Peter},
title = {Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70640}
}
EUVIMED